John Tchelingerian, PhD, a well-recognized biotech entrepreneur, brings scientific, deal making and commercial experience to the team Mont-Saint-Guibert, Belgium, December 8, 2014 - Promethera Biosciences, a Belgian biotechnology company developing PrometheraA HepaStem, a cell-based therapy for the treatment of in-born errors of metabolism and acquired liver diseases, today announces that Dr John Tchelingerian has joined the company as chairman of the board. He will support Promethera to catalyze transformative transactions in the future.
http://ift.tt/1ucT91N
http://ift.tt/1ucT91N
No comments:
Post a Comment